A Phase II Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anti-PD-1 Antibody IBI308 in Patients With Hepatocellular Carcinoma
Latest Information Update: 08 Jul 2022
At a glance
- Drugs Sintilimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 08 Jul 2022 New trial record
- 07 Jun 2022 Results (At data cutoff (Dec 28th, 2021, n=25 )presented at the 58th Annual Meeting of the American Society of Clinical Oncology